Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease
Objective: We aimed to study the association between glutamatergic system gene polymorphisms (SLC1A2 – gene, coding excitatory acids transporter, and GRIN2A gene, coding a subunit…Alterations of cortical metabotropic glutamate receptor-mediated signaling in patients with Parkinson’s disease
Objective: To evaluate expression of brain metabotropic glutamatergic receptor 5 and the relationship with clinical measures in Parkinson’s disease patients. Background: Metabotropic glutamate receptor 5…Anti-glutamatergic effect of safinamide in Parkinson’s Disease: A TMS study
Objective: To test the effect of safinamide, at the doses of 50 and 100 mg/day, on primary motor cortex (M1) excitability and glutamatergic neurotransmission in…Serum glutamate is associated with the motor subtype of Parkinson’s disease
Objective: We aimed to study the concentration of glutamate in the serum of patients with Parkinson's disease (PD) and its connection with clinical variants of…The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of highly-selective metabotropic glutamate 2 receptor (mGluR2) activation at alleviating and preventing the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Chronic…Long-term efficacy of safinamide on mood in Parkinsonian patients with fluctuations
Objective: The present post-hoc analysis of the results of two pivotal trials (016 and 018) investigated the effects of safinamide 100 mg/day on mood in…SLC6A17 mutations are not a common cause of intellectual disability and movement disorders in a large cohort of consanguineous Iranian families
Objective: To determine the prevalence of SLC6A17 mutations in a cohort of Iranian patients with intellectual disability and movement disorders. Background: Mutations in the SLC6A17…Density of metabotropic glutamate receptors subtype 1 in de novo patients with Parkinson’s disease using 11C-ITMM PET
Objective: To investigate the mapping of metabotropic glutamate receptor subtype 1 (mGluR1) in elderly normal and de novo patients with Parkinson's disease (PD) using N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-4-11C…Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia
Objective: To evaluate the role of the atypical vesicular glutamate transporter 3 (VGLUT3) and the vesicular acetylcholine transporter (VAChT) in L-DOPA-induced dyskinesia. Background: Parkinson's disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.